Pneumococcal Vaccines Market

Pneumococcal Vaccines Market: North America to Register Fastest Growth During the Forecast Period: Global Industry Analysis 2013 - 2017 and Opportunity Assessment 2018 - 2028

  • 2018-07-19
  • REP-GB-7078
  • 187 pages
  • PDF PPT EXCEL
Pneumococcal Vaccines Market

An Incisive, In-depth Analysis on the Pneumococcal Vaccines Market

This study offers a comprehensive, 360 degree analysis on the Pneumococcal Vaccines market, bringing to fore insights that can help stakeholders identify the opportunities as well as challenges. It tracks the global Pneumococcal Vaccines market across key regions, and offers in-depth commentary and accurate quantitative insights. The study also includes incisive competitive landscape analysis, and provides key recommendations to market players on winning imperatives and successful strategies.

Pneumococcal disease is an infection caused by streptococcus pneumonia. Pneumococcal infection can result in pneumonia, bacteremic pneumonia, bacteremia, meningitis, bloodstream infection and middle ear infection. There are two main types of pneumococcal diseases, namely non-invasive and invasive pneumococcal diseases. Invasive pneumococcal diseases, such as bacteremia (sepsis), meningitis and bacteremic pneumonia, tend to be more serious compared to non-invasive. Serotypes 1, 4, 5, 7F, 8, 12F, 14, 18C, and 19A are more likely to cause invasive pneumococcal diseases.

According to the World Health Organization, pneumonia accounted for 16% deaths of children aged under 5 year in 2015. Pneumococcal vaccines are used against streptococcus pneumonia. There are 2 types of pneumococcal vaccines available—conjugate vaccines and polysaccharide vaccines. The WHO has recommended pneumococcal conjugate vaccines in the routine immunization for children. In this report, the pneumococcal vaccines market is further categorized into product type and distribution channel. The report provides market size and forecast for pneumococcal vaccines against streptococcus pneumonia, inclusive of both types of vaccines. The report analyses the demand for pneumococcal vaccines form pharmacies, public health agencies, community clinics and other distribution channels.

Market Value and Forecast

In terms of revenue, the global pneumococcal vaccines market is projected to expand at 9.1% CAGR over the forecast period of 2018–2028. The pneumococcal vaccines market is expected to be valued at US$ 18,456.5 Mn by 2028 end. The addition of pneumococcal vaccine national immunization programs and development of new pneumococcal vaccines are expected to boost the growth of the global pneumococcal vaccines market over the forecast period. According to the World Health Organization, pneumococcal vaccines were added in the national immunization programs of 138 countries till 2017.

Market Dynamics

The global demand for pneumococcal vaccines is growing as a result of increasing initiatives by government and private organizations to provide vaccination in developing countries. Public–private partnerships to provide low-cost pneumococcal vaccines in middle-income countries is also expected to propel the growth of the pneumococcal vaccines market. Pneumococcal vaccines are introduced in more than 57 Gavi-supported countries under the advance market commitment. Development of pneumococcal vaccines for all age groups is expected to create favourable growth opportunities for the pneumococcal vaccines market. Likewise, increasing awareness among parents regarding vaccination, catch up champignons to reduce IPD risk and partnerships & funding for development of new vaccines are expected to boost the growth of the global pneumococcal vaccines market. However, low immunization coverage for new pneumococcal vaccines, slow introduction of vaccines in middle-income countries, low awareness among older population regarding pneumococcal vaccination are some of the factors expected to hamper the growth of the pneumococcal vaccines market.

Key Regions

Geographically, the global pneumococcal vaccines market is segmented into seven major regions viz. North America, Latin America, Western Europe, Eastern Europe, Asia Pacific (Asia-Pacific excluding Japan), Japan and the Middle East & Africa (MEA). In terms of value, North America was the dominant regional market for pneumococcal vaccines in 2017 and is expected to expand at high CAGR of 10.2% over the forecast period of 2018–2028.  Asia Pacific is expected to contribute significant revenue share in the global pneumococcal vaccine market due to increasing government funding and the addition of pneumococcal vaccines in national immunization programs in the region.

Pneumococcal-Vaccines-Market.jpg

Key Players

Examples of some of the key players identified in the global pneumococcal vaccines market are Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc., and Merck & Co., Inc., among others. Manufacturers are focusing on research and development activities to develop multivalent pneumococcal vaccines. Pfizer Inc. and GlaxoSmithKline Plc. have collaborated with Gavi vaccine alliance to supply their pneumococcal vaccines in Gavi-supported countries. Through this collaboration, both the companies have increased their presence in the market and contribute to the immunization program.

Future Market Insights (FMI) offers a 10-year forecast on the global pneumococcal vaccines market. The primary objective of the report is to offer updates and information related to opportunities in the global pneumococcal vaccines market.

Report Description

In terms of revenue, the global pneumococcal vaccines market is expected to register a CAGR of 9.1% during the forecast period of 2018–2028. The primary objective of the report is to offer insights on the market dynamics that can influence the growth of the global pneumococcal vaccines market over the forecast period. Insights on the key trends, drivers, restraints, value forecasts and opportunities for companies operating in the global pneumococcal vaccines market are presented in the report.

The global demand for pneumococcal vaccines is increasing as a result of the large burden of pneumonia-related child mortality rate. Pneumonia is the leading cause of child deaths. 16% of all deaths under age 5 are due to pneumonia. The governments across the globe are focusing on reducing the mortality rate with the help of pneumococcal immunization, which is expected to fuel the growth of the pneumococcal vaccines market. Besides, the support from Gavi to low-income countries for pneumococcal immunization is expected to boost the growth of the pneumococcal vaccines market. Availability of cost-effective vaccines in developing countries as well as favourable reimbursement policies for pneumococcal conjugate and polysaccharide vaccine are expected to spur the demand for pneumococcal vaccines.

Research & development activities for the development of new pneumococcal vaccines, balanced supply and demand, government and private funding for pneumococcal vaccines are expected to boost the demand for pneumococcal vaccines over the forecast period. Manufacturers are focusing on mergers and collaborations for the development of new vaccines, whereas increasing pharmacy-based pneumococcal immunization is expected to create huge opportunities for growth of the pneumococcal vaccines market.

The revenue of the pneumococcal vaccines market in North America is expected to grow at the high rate. To understand and assess opportunities in this market, the report offers the market forecast on the basis of product type and distribution channel. The report provides analysis of the global pneumococcal vaccines market in terms of market value (US$ Mn).

The report begins with the market definition, followed by definitions of the different pneumococcal vaccines types. The market dynamics section includes FMI’s analysis on key trends, drivers, restraints, opportunities and macro-economic factors influencing the growth of the global pneumococcal vaccines market. Opportunity analysis provided in the section allows clients to better equip with crystal clear decision-making insights

The subsequent section of the report provides analysis of the market on the basis of regions and presents forecast in terms of value for the next 10 years. The regions covered in the report include:

  • North America

    • U.S.

    • Canada

  • Latin America

    • Brazil

    • Mexico

    • Rest of Latin America

  • Western Europe

    • Germany

    • Italy

    • France

    • Spain

    • U.K.

    • Rest of Western Europe

  • Eastern Europe

    • Russia

    • Poland

    • Rest of Eastern Europe

  • Asia Pacific Excluding Japan

    • India

    • China

    • ASEAN

    • Australia & New Zealand

    • Rest of APEJ

  • Japan

  • Middle East & Africa (MEA)

    • GCC Countries

    • South Africa

    • Rest of MEA

The next section provides competitive edge of the global pneumococcal vaccines market. This section is primarily designed to provide clients with an objective and detailed comparative assessment of the key providers specific to a market segment in the pneumococcal vaccines market. The competition landscape section provides dashboard view of the activities of major players in the global pneumococcal vaccines market. The company profiles section provides information on the key offerings of each player in the global pneumococcal vaccines market, their direct & indirect presence, revenue, key developments and strategies and SWOT analysis. The key players included in this report are Pfizer Inc., Sanofi S.A., GlaxoSmithKline Plc., Merck & Co., Inc.

The next section analyses the market on the basis of product type and presents the forecast in terms of value (US$ Mn) for the next 10 years. The product types covered in the report include:

  • Pneumococcal Polysaccharide Vaccines

  • Pneumococcal Conjugate Vaccines

The next section analyses the market on the basis of the distribution channel and presents forecast in terms of value (US$ Mn) for the next 10 years. The distribution channels covered in the report include:

  • Pharmacies

  • Community Clinics

  • Public Health Agencies

  • Others

In addition, we have considered Year-on-Year (Y-o-Y) growth to understand the predictability of the market and identify growth opportunities for companies operating in the global pneumococcal vaccines market.

Another key feature of this report is the analysis of the key segments in terms of absolute dollar opportunity. This is usually overlooked while forecasting the market. However, absolute dollar opportunity is critical for assessing the level of opportunity that a provider can look to achieve, as well as to identify potential resources from a sales and delivery perspective for services offered by pneumococcal vaccines market. To understand the key segments in terms of their growth and performance in the global pneumococcal vaccines market, Future Market Insights has developed a market attractiveness index. The resulting index will help providers to identify the existing market opportunities.

Pneumococcal Vaccines Market Reports - Table of Contents

Get in touch

Harish Tiwari

Harish Tiwari

Global Head - Business Development

Pranay Mhaisekar

Pranay Mhaisekar

Business Development

* indicates mandatory fields.

Our Clients


CASE STUDIES

See how our work makes an impact.

At FMI, we design strategies that are adaptive, impactful, and implementable.

Request Sample Ask An Analyst Request Special Price Request Methodology